PRESS RELEASE DUBLIN.

The company name change comes after the acquisition of Allergan inMarch 2015and the acceptance of the name transformation by Actavis shareholders onJune 5. The mix of Allergan and Actavis produced one of the world's top 10 10 pharmaceutical companies by income and a leader in a fresh industry model – Growth Pharma. Today is an exciting day time for Allergan and our 30,000 workers around the global world who’ve helped us reach this particular moment, saidBrent Saunders, CEO and President of Allergan. By adopting the Allergan name, we are ensuring that our corporate identity reflects the transformation of our business within the pharmaceutical market and our placement as a dynamic new breed of firm – a innovator in Growth Pharma.The acquisition provides Abbott with a respected existence in the growing area of non-surgical treatment for structural cardiovascular disease. The MitraClip system is an investigational device in the United States and happens to be in clinical trials. ‘Evalve’s innovative valve fix technology gives us the potential to supply new treatment plans for millions of sufferers with mitral regurgitation around the world,’ said Robert Hance, senior vice president, vascular, Abbott.